U.S. Markets closed

Solid Biosciences shares drop 70% on disappointing Duchenne data

Allison DeAngelis
Solid Biosciences shares drop 70% on disappointing Duchenne data

Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.